It is often said that the one constant is change. And in the world of pharmaceutical research and development in the last decade or so, this is particularly evident.  Not only has the criteria behind intellectual property (IP) protection and patentability changed, but so has the size and shape of research organizations, as well as drug targets. Until recently, companies were primarily…